Please, note that all participants of the congress will have access to the presentations and posters for 1 year.

Congrats to Eurordis for having rearranged this conference into virtual event in such a successful way and short time!

Don’t forget the EJP RD Helpdesk is available for any inquires and services provided by the EJP RD including Clinical Trials Support Office and Innovation Management Advice.

Registration for this course is now open, deadline is 20 July.

The course will take place in Istanbul, Turkey on 12-14 October. A mitigation plan due to Covid-19 is in place. The aim is to teach participants about the evaluation of the pathogenic nature and clinical significance of genetic variants, on the criteria that have to be set to the NGS analysis pipelines and on the use of international databases.

The targeted audience is: Laboratory scientists (European Board Medical Genetics registered), junior scientists, clinical geneticists, other medical doctors in training, policy makers and assessors for laboratory accreditation, and patient representatives, with a basic knowledge in biology or medicine.

To ensure active participation and exchange with teaching staff and fellow participants, a maximum of 35 participants will be admitted to the training course. There are #2 travel fellowships available, participants from EU-13 countries and Turkey are encouraged to apply.

The workshop and registration are free of charge.

• Launching Advisory Committees for Therapeutics (ACT) in rare diseases. Joanne Lee, Newcastle University, UK
• Intranodal Magnetic Resonance Lymphangiography Studies Workshop. Willemijn M. Klein, Radboud University Medical Center Nijmegen, The Netherlands. VASCERN
• Methods to study rare diseases, their causes and treatments: The Basics & Beyond.
  Olaf Dekkers. Leiden University Medical Center (LUMC), The Netherlands. Endo-ERN

GA4GH 8th Plenary is going virtual, save the dates: September 29 – 30 2020. The event will bring together organizations and stakeholders from the genomics and health community for two days of keynotes, talks, updates, and workshops that will focus on advancing development work for the immediate data sharing needs of the community. More details, including registration, will be shared in the coming weeks.

ELIXIR All Hands 2020 meeting will take place virtually 8 - 10 June 2020 and will bring together members of the ELIXIR community from across the ELIXIR Nodes and collaborators from partner organizations. ELIXIR’s achievements and activities will be reviewed and plans for the future will be discussed. Participants from ELIXIR Nodes and invited guests are welcome. Program is available. Registration and posters submission are open.

Latest progress on Horizon Europe’s Implementation Strategy provides the framework for carefully designed rules and efficient processes across the entire program and project life cycle. This is a living document that allows the program to deliver its impacts as efficient and user-friendly as possible and will receive further updates. The rules and simplification measures put in place for Horizon 2020 were widely acknowledged by stakeholders as a big step towards a more attractive and easier to use program, based on this experience, work has been ongoing on this document to set out how the program will be managed in practice to achieve its ambitious objectives.

Boosting delivery of rare disease therapies: the IRDiRC Orphan Drug Development Guidebook has been published in Nature Reviews Drug Discovery. The paper is authored by the Orphan Drug Development Guidebook (ODDG) Task Force that is helping to reach the IRDiRC goal 2 ‘1000 new therapies for rare diseases will be approved’ by 2027.

The aim is to support drug development for rare diseases by organizing available tools in the USA, Europe and Japan into a standardized framework and make them ready for optimal uses. The ODDG materials are now available on a user-friendly website, to guide those who are less familiar with this complex enterprise. By enhancing the use of available tools, delays in development timelines can be avoided, risks and costs reduced, patient and regulatory acceptability improved.

ERN TRANSPLANT-CHILD PATIENT’S GUIDE gives some important recommendations for transplanted patients and their families to take care of their health after this complex procedure. The guide is common for all types of transplants and includes different aspects of the post-transplantation process such as medication, rejection, infections, and emotions

The Patient’s Guide currently is available in English, Spanish, and French.

Covid-19 Global Response – Communication Toolkit developed by the European Union (EU) is now available. Take advantage of this resource to join the social media campaign and help to raise awareness on the important initiatives led by the EU on the fight against Covid-19. The opening event of Coronavirus Global Response, a worldwide pledging effort to raise €7.5 billion of funding to rapidly develop universally available and affordable diagnostics, treatments, and vaccines against the virus, has already raised €7.4 billion, including a significant contribution of €1 billion mobilized by Horizon 2020.

Covid-19: Commission issues guidance to mitigate clinical trial disruption in the EU in order to ensure their continuation in the EU during the Covid-19 pandemic. The aim is to mitigate the disruption of clinical research and therefore the negative effects of the pandemic, without compromising on quality and safety. The guidance offers recommendations for simple and flexible measures to respond to the current situation, and to ensure that patients participating in clinical trials across the EU can continue receiving their medicines.

ECRIN COVID-19 TASKFORCE has been established with its national partners to confront the pandemic. ECRIN is working together with the healthcare partners to take care of patients as first priority. At the same time, ECRIN is also supporting the researchers by joining forces worldwide to find a cure and a vaccine.

Sharing research data is a critical step in this global cooperation effort and the ECRIN Taskforce, organized in #8 different initiatives, is focused on high relevant topics around research, clinical trials, policy, and networking.

ELIXIR COVID-19 SLACK WORKSPACE has been launched to discuss and exchange ideas on Covid-19 research initiatives, consider collaboration opportunities across ELIXIR Nodes, and share results of work on the virus with other ELIXIR members. Please, get in touch with ELIXIR If you are interested in joining this initiative.

• SCIENTIFIC PROJECT MANAGER, ERN-EYE, Hôpitaux Universitaires de Strasbourg (HUS). France 
• HELPDESK ASSISTANT, ERN-NMD, Institution of Myology. France
• TECHNOLOGY TRANSFER ASSOCIATE, Fondazione Telethon. Italy

This initiative has received funding from the European Union's Horizon 2020
research and innovation programme under GA N°825575

EJP RD is coordinated by the National Institute for Health and  Medical Research (INSERM)

Wondering why you receive this email? Click here to update your preferences.